Floatz logo

PRAZOSIN

Post-traumatic Stress Disorder (PTSD)

Otsuka Pharmaceutical Development & Commercialization, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Post-traumatic Stress Disorder (PTSD) cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Queen's University
Phase 4BBB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
Paroxetine
University of Washington
Phase 4BB
Cipralex
New York State Psychiatric Institute
Phase 4BB
Methylphenidate
VA Office of Research and Development
Phase 4BB

View all 44 →

Same molecule, other indications

PRAZOSIN is also rated in:

Gastrointestinal HemorrhageDormant
BB
Indicative ·
69 / 100
View asset →
Post-Traumatic HeadacheDormant
BB
Indicative ·
69 / 100
View asset →
portal hypertensionDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →